A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results
Titel:
A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results
Auteur:
Pivot, X. Bondarenko, I. Nowecki, Z. Dvorkin, M. Trishkina, E. Ahn, J.-H. Im, S.-A. Sarosiek, T. Chatterjee, S. Wojtukiewicz, M.Z. Shparyk, Y. Moiseyenko, V. Bello III, M. Semiglazov, V. Lee, Y. Lim, J.